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Abstract
Little is known about the real-world treatment patterns of elderly women with advanced ovarian cancer. In this
retrospective study, using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we investigated
the variety and duration of cytotoxic regimens received by this population. Half of the patients did not complete
ﬁrst-line therapy, a quarter of those eligible initiated maintenance, and no single treatment strategy dominated
second-line therapy, indicating a substantial unmet need in therapy options.
Background: Over the past decade, chemotherapy treatment for patients with advanced ovarian cancer has
expanded, with platinum-based and taxane therapy remaining the backbone. Elderly patients have received little
attention, and less is known about the variation and duration of agents elderly women receive for ﬁrst-line, mainte-
nance, and second-line therapy. Patients and Methods: Using SEER linked to Medicare claims data, we identiﬁed a
cohort of women (older than 65 years) with advanced epithelial ovarian cancer who received ﬁrst-line and/or main-
tenance therapy between 2003-2009. Over the same period, we identiﬁed women who received second-line therapy.
We examined the variety of cytotoxic regimens and duration of therapy. Results: In the patient group, 10,695 patients
were eligible for chemotherapy, and 5357 had evidence of receiving any chemotherapy. The ﬁrst-line sample included
2509 patients, the maintenance sample included 306 patients, and the second-line sample included 1890 patients.
Among ﬁrst-line patients, paclitaxel and carboplatin was the most common regimen. Approximately half of the patients
did not successfully complete ﬁrst-line treatment. Of those eligible for maintenance therapy, about one-quarter of the
patients initiated a maintenance regimen, and approximately 10% of those who initiated maintenance therapy
completed at least 40 weeks. The most common second-line treatment included platinum-based and taxane therapy,
if the patient was platinum-sensitive, or a single-agent anthracycline therapy otherwise. Conclusion: Additional
research should address low ﬁrst-line treatment completion rates. Most patients eligible for maintenance therapy do
not initiate it, and multiple treatment strategies predominate in second-line therapy. There remains a substantial unmet
need in therapy options for ovarian cancer.
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In 2012, an estimated 22,280 American women were newly
diagnosed with ovarian cancer, most of whom will die of the disease,
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http://dx.doi.org/10.1016/j.cogc.2013.02.001ﬁfth leading cause of cancer death among women in the United
States.1 From 2005 to 2009, the median age at diagnosis for ovarian
cancer was 63 years of age, with incidence and risk of comorbidities
increasing with age. In particular, women aged 65 and older
accounted for more than 45% of incident cases of ovarian cancer
in the United States; the age-adjusted incidence in this group
was 46.8/100,000, peaking in the 80 to 84 age category with
an incidence of 53.3/100,000, compared with an incidence of
34.0/100,000 in women aged 60 to 64.2 Based on deaths from
2005 to 2009, the age-adjusted mortality rate for ovarian cancer was
42.3/100,000 women aged 65 and older, with a median age at death
of 71 years. Though ovarian cancer mortality is decreasing—theClinical Ovarian and Other Gynecologic Cancer December 2012 - 67
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cancer was approximately 2.0% (P < .05) from 2002 to
2009 after being nonsigniﬁcantly different from 0 from 1998 to
2002—older patients tend to experience poorer survival rates than
younger patients, even after adjusting for stage, residual disease,
and performance status.3
The past decade has seen signiﬁcant changes in the available ther-
apeutic agents and the treatment strategies for advancedovarian cancer.
The use of paclitaxel and platinum-based regimens signiﬁcantly
improved progression-free survival and overall survival.4 Docetaxel, in
selective cases, presented an alternative to paclitaxel (SCOTROC
[Scottish Randomised Trial in Ovarian Cancer] trial),5 as did single
platinum agent therapies (GOG [Gynecologic Oncology Group] 132
trial).6 Maintenance therapy emerged as an option after the results of a
randomized trial conducted by Markman et al (GOG 178 trial),
demonstrating that administration of single-agent paclitaxel to women
with advanced ovarian cancer who attained a clinically deﬁned com-
plete response to platinum/paclitaxel-based chemotherapy could
substantially improve progression-free survival.7 Follow-up data indi-
cated a continued statistically signiﬁcant improvement in progression-
free survival.8 However, other research failed to ﬁnd evidence of
improvement in outcomes associated with this strategy.9,10 Second-
line therapy options have expanded in recent years to include carbo-
platin in conjunction with either taxane (ICON [International
Collaborative Ovarian Neoplasm] trial),11 gemcitabine (AGO-OVAR
[Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
Ovarialkarzinom] trial),12 or liposomal anthracycline (CALYPSO
[Caelyx in Platinum Sensitive Ovarian patients] trial)13 for platinum-
sensitive patients. Patients that are refractory to platinum-based ther-
apy are often treated with a variety of agents, with the most notable
agents being liposomal anthracycline,14-16 topotecan,17-20 gemcita-
bine,21-24 and in selected cases, angiogenesis inhibitors.25
The survival of patients with ovarian cancer has improved over the
past few decades, likely attributable to advances in chemotherapy and
surgery,26 although the beneﬁts from these advances have not been
uniform among women.27 Research reveals considerable variation in
access to chemotherapy and treatment patterns for patients with
ovarian cancer. Polsky et al found that both geography and clinical
characteristics (ie, stage at diagnosis, age, and comorbidities) play a
role in determining who gets chemotherapy.28 Thrall et al found that
a substantial proportion of women received chemotherapy as primary
treatment for advanced ovarian cancer, but most of these patients did
not have cancer-directed surgery, which is contrary to guidelines.29
Generally, research has shown that elderly women with ovarian
cancer receive more conservative treatment regimens, including
lower rates of chemotherapy and surgery, and have poorer survival
compared with younger patients with ovarian cancer.27,30-33 Treat-
ment decisions for elderly patients with ovarian cancer are fraught
with additional uncertainty, for example, higher rates of comorbid-
ities and the assumption of increased risk of toxicity compared with
the nonelderly.34 However, some research has demonstrated that
elderly patients are able to tolerate surgery and ﬁrst-line chemo-
therapy as well as their younger counterparts.32,35
The research objective of this study was to characterize treatment
patterns in the elderly from 2003 and onward by examining the
regimens used and duration of therapy in the ﬁrst-line, mainte-
nance, and second-line treatment settings.Clinical Ovarian and Other Gynecologic Cancer December 2012Patients and Methods
Data
The Surveillance, Epidemiology, End Results (SEER) database,
provided by the National Cancer Institute (NCI), linked to
Medicare health care claims records provided by the Centers for
Medicare and Medicaid Services (CMS)36 were used in this analysis.
The SEER cancer registry compiles data on newly diagnosed cancer
patients, including information on tumor site, histology, stage, in-
dividual demographic information, and primary surgical treatment
for cancers occurring in approximately 26% of the US population.37
An estimated 97% of incident cancer cases are captured in the
SEER regions, which are representative of the US population.38,39
For persons older than the age of 65, the SEER data are linked to
Medicare ﬁles, allowing for the identiﬁcation and sequencing of
the agents based on the Healthcare Common Procedure Coding
System (HCPCS) codes that a patient received after diagnosis.37
The SEER-Medicare data include all Medicare-eligible persons
appearing in the SEER data who were diagnosed with cancer
through 2007 and their Medicare claims through 2009.37
Sample Selection
Women in the SEER-Medicare database were identiﬁed if diag-
nosed with ovarian cancer (SEER cancer site record of 50 and the
ICD-O-3 site code of C56.9) between January 1, 1991 and
December 31, 2007 (n ¼ 43,536), which was the extent of the
SEER data available in the Medicare-SEER linked dataset during
the time of this study. Women were included if they had stage II,
III, or IV epithelial ovarian cancer (deﬁned by the American Joint
Cancer Committee indicating advanced disease and based on
morphology codes: 8050-8052, 8140, 8141, 8143, 8147, 8255,
8260-8263, 8310, 8313, 8323, 8380-8383, 8440, 8441, 8450,
8460, 8461, 8470, 8471 8480-8482, 8570-8574, and 8980-8982).
Women were also required to be older than the age of 65 on their
diagnosis date, have only 1 primary tumor, and be covered
continuously by Medicare Parts A and B from the 6 months before
the ﬁrst chemotherapy treatment through the end of treatment.
Medicare claims data recording the date and type of chemo-
therapy administration for each patient were available from January
1, 1991 to December 31, 2009, which was the extent of the
Medicare claims data available in the Medicare-SEER linked dataset
during the time of this study. Patients who received a chemotherapy
agent that was not consistent with the National Comprehensive
Cancer Network (NCCN) guidelines25 for ﬁrst-line, maintenance,
or second-line treatment of ovarian cancer were excluded. Patients
were required to have a ﬁrst chemotherapy treatment within 1 year
of their SEER diagnosis date.
Patient Characteristics
The SEER database included a detailed set of patient socio-
demographic variables, including marital status, race, and median
household income from zip code of residence in the 2000 census
data. Tumor characteristics including stage, grade, and histology
were also available.
First-line Therapy Sample
Patients were included in ﬁrst-line treatment samples based on
evidence of ﬁrst use of chemotherapy after January 1, 2003. Patients
Scott J. Johnson et alwere included in 1 of 6 possible ﬁrst-line chemotherapy regimens,
including: (1) carboplatin and paclitaxel; (2) carboplatin and doce-
taxel; (3) single-agent carboplatin or cisplatin; (4) single-agent
paclitaxel; (5) cisplatin and paclitaxel; or (6) carboplatin or cis-
platin and cyclophosphamide, if these agents were the only drugs
given to the patient during the initial 4 weeks of treatment. An
“Other” category included all other patients who had evidence of
chemotherapy use but received combinations of agents different
from those in the 6 speciﬁc regimens in the ﬁrst 4 weeks of therapy
(eg, patients with evidence of use of carboplatin, docetaxel, and
cisplatin).
For each speciﬁc ﬁrst-line treatment sample, the length of
continuous treatment was estimated as the time interval during
which a patient received only ﬁrst-line chemotherapies. Continuous
treatment was assumed to end either after 24 weeks of continuous
ﬁrst-line therapy; if a patient had more than 10 weeks between
cycles of initially administered drugs; if a patient had received a
second-line drug; or if a patient had had no further evidence of
chemotherapy treatment.
Patients were considered to have successfully completed ﬁrst-line
therapy if they received at least 6 cycles of their most used ﬁrst-line
chemotherapy drug during the 24-week ﬁrst-line period. A cycle was
deﬁned as a unique claim per service date for a speciﬁc chemo-
therapy agent, identiﬁed based on claims that contained an HCPCS
code that represents a speciﬁc type of chemotherapy (eg, J9045
refers to carboplatin). See Supplementary Table 1 for a list of
HCPCS codes used to identify the individual chemotherapies.
The average duration of continuous ﬁrst-line treatment, average
number of cycles of each regimen, the proportion of patients who
had additional ﬁrst-line drugs during their treatment episode (eg,
switching from carboplatin and paclitaxel to carboplatin and doce-
taxel), reason for continuous treatment ending according to the
claims algorithm, and percentage of patients successfully completing
therapy were estimated. We also compared the ﬁrst-line completion
rates of women aged 65 to 74 years with women 75 years and older
to assess the effect of age on ﬁrst-line treatment.
Maintenance Therapy Sample
Patients were included in the maintenance therapy sample if they
had successfully completed ﬁrst-line treatment and received subse-
quent doses of paclitaxel, docetaxel, or bevacizumab within 3
months of their last dose of ﬁrst-line chemotherapy (ie, the end of
their last cycle of ﬁrst-line treatment during the 24-week ﬁrst-line
period). Maintenance therapy samples were deﬁned for patients
who successfully completed ﬁrst-line treatment. The maintenance
period was assumed to last a maximum of 52 weeks based on the
original trial by Markman and colleagues (GOG 178), in which 1
maintenance treatment arm consisted of 12 cycles of single-agent
paclitaxel administered every 28 days.7
The length of continuous maintenance treatment was estimated
based on the time from the ﬁrst administration until the ﬁnal
administration of the maintenance agent. The ﬁnal administration
occurred if there was 1 of the following events: a gap in treatment of
maintenance chemotherapies that was longer than 10 weeks; an
administration of a second-line chemotherapy agent; 52 weeks from
the initial maintenance treatment administration; or there was no
further evidence of the maintenance therapy. Any drug that apatient previously received during ﬁrst-line therapy was allowed
during the maintenance period as long as there was not a 6-month
gap between administrations of that particular agent, which would
indicate second-line treatment.
Duration of continuous maintenance treatment, average number
of cycles of each maintenance regimen, number of cycles completed,
and reason for continuous maintenance episode end were estimated.
Maintenance initiation rates were compared for women aged 65 to
74 years and women 75 years and older.
Patients receiving maintenance therapy were followed for the rest
of the observation period in the data to estimate the percentage who
ever received a second-line drug and the time from the end of a
patient’s ﬁrst-line to her second-line drug among those who received
a second-line drug.
Second-line Therapy Sample
To investigate second-line treatment patterns during the same
time period, a separate second-line therapy sample included patients
who received any second-line therapy after January 1, 2003 and, as
such, were not required to have been in the ﬁrst-line sample. For
example, a patient could have received ﬁrst-line therapy in 2001 and
subsequent second-line therapy in 2003 and thus included in the
second-line sample but not the ﬁrst-line sample. This cohort was
deﬁned based on the initial second-line regimen that the patient was
given, including drugs listed as potential second-line therapies based
on NCCN guidelines25 (eg, liposomal anthracycline, gemcitabine,
topotecan), a ﬁrst-line drug that the patient had never received
before (eg, cisplatin after ﬁrst-line carboplatin and paclitaxel), or a
ﬁrst-line drug that the patient previously received but when there
was at least a 6-month gap between treatments (eg, ﬁrst-line car-
boplatin and paclitaxel followed by paclitaxel maintenance, with a
26-week or longer gap between the last paclitaxel maintenance cycle
and the ﬁrst second-line paclitaxel cycle).
Patients were included in a speciﬁc second-line treatment sample
based on exclusively receiving platinum-sensitive agents (eg, a
platinum agent alone or with paclitaxel, docetaxel, or gemcitabine or
liposomal anthracycline) or single-agent platinum-refractory therapy
(eg, paclitaxel, docetaxel, doxorubicin, topotecan, or bevacizumab)
for the ﬁrst 4 weeks of second-line therapy. Patients who received
other second-line agents in some combination different from these
groups were included in an “other” category.
Continuous initial second-line treatment was assumed to last
until the ﬁrst of any of the following events occurred: a patient had a
gap between the same second-line treatments of more than 10
weeks; had no further evidence of chemotherapy; received a dif-
ferent second-line drug; or December 31, 2009, the point at which
the data were censored.
Duration of treatment, average number of cycles, and reason for
second-line treatment ending were measured.
Per SEER policy, results were suppressed when cell sizes included
fewer than 11 persons.
Results
In the SEER data, 10,695 patients met selection criteria and were
eligible for chemotherapy. Based on the linked Medicare data, 5357
had evidence of receiving any chemotherapy. The ﬁrst-line treat-
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Table 1 Demographic, Clinical, and Pathologic Characteristics, According to Treatment Group
Characteristic First-line Maintenance Second-line
Sample (Patients) 2509 306 1890
Age, Mean (SD), years 75.4 (6.2) 75.1 (5.8) 75.9 (5.8)
Age Range
65-69 years 595 (23.7) 95 (31.0) 350 (18.5)
70-74 years 643 (25.6) 88 (28.8) 556 (29.4)
75-79 years 668 (26.6) 71 (23.2) 509 (26.9)
80-84 years 423 (16.9) 40 (13.1) 346 (18.3)
85 years and older 180 (7.2) 12 (3.9) 129 (6.8)
Race
White 2260 (90.1) 284 (92.8) 1714 (90.7)
Black 122 (4.9) a 76 (4.0)
Other 127 (5.1) a 100 (5.3)
Household Income, Median
(Interquartile Range)
$49,659 ($36,723-$64,360) $51,661 ($38,558-$66,151) $49,501 ($36,636-$64,188)
Marital Status
Married 1203 (47.9) 171 (55.9) 962 (50.9)
Not married 1306 (52.1) 135 (44.1) 928 (49.1)
Region
Northeast 588 (23.4) 49 (16.0) 444 (23.5)
Midwest 319 (12.7) 38 (12.4) 227 (12.0)
South 438 (17.5) 54 (17.6) 329 (17.4)
West 1164 (46.4) 165 (53.9) 890 (47.1)
Area of Residence
Large metropolitan 1434 (57.2) 177 (57.8) 1076 (56.9)
Metropolitan 720 (28.7) 92 (30.1) 544 (28.8)
Urban 149 (5.9) 21 (6.9) 117 (6.2)
Less urban 169 (6.7) a 126 (6.7)
Rural 37 (1.5) a 27 (1.4)
Stage
Stage II 216 (8.6) 16 (5.2) 119 (6.3)
Stage III 1370 (54.6) 159 (52.0) 1110 (58.7)
Stage IV 923 (36.8) 131 (42.8) 661 (35.0)
Grade
Grade I/II 339 (13.5) 33 (10.8) 247 (13.1)
Grade III/IV 1382 (55.1) 177 (57.8) 1086 (57.5)
Unknown 788 (31.4) 96 (31.4) 557 (29.5)
Histology
Adenocarcinoma 1107 (44.1) 138 (45.1) 782 (41.4)
Papillary serous 1144 (45.6) 148 (48.4) 944 (49.9)
Carcinosarcoma a 0 (0.0) a
Clear cell 47 (1.9) a 29 (1.5)
Endometrioid 133 (5.3) a 87 (4.6)
Mucinous 55 (2.2) a 33 (1.7)
Other epithelial a a a
Index Year
2003 549 (21.9) 67 (21.9) 317 (16.8)
2004 480 (19.1) 51 (16.7) 297 (15.7)
2005 499 (19.9) 70 (22.9) 308 (16.3)
2006 504 (20.1) 57 (18.6) 319 (16.9)
2007 420 (16.7) b 284 (15.0)
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Table 1 Continued
Characteristic First-line Maintenance Second-line
2008 57 (2.3) a 258 (13.7)
2009 0 (0.0) a 107 (5.7)
Data are presented as n (%) except where otherwise noted.
aCell contents indicate n  20 patients but are suppressed to prevent cells with n < 11 from being derivable.
bCell contents indicate 45 to 60 patients but are suppressed to prevent cells with n < 11 from being derivable.
Scott J. Johnson et alincluded 306 patients, and the second-line treatment sample
included 1890 patients.
Patient Characteristics
Patient characteristics for the ﬁrst-line treatment, maintenance,
and second-line samples are shown in Table 1. The average patient
age was approximately 75. Patients receiving maintenance therapy
had marginally later stage disease (stage IV: 42.8% vs. 36.8% in
ﬁrst-line and 35.0% in second-line).
First-line Therapy
First-line treatment patterns are shown in Table 2. Most ﬁrst-line
patients (74.8%, n ¼ 1877) received a ﬁrst-line regimen of carbo-
platin and paclitaxel. On average, these patients were treated with
5.5 cycles of paclitaxel and 5.3 cycles of carboplatin, and the average
length of ﬁrst-line treatment was approximately 103.9 days (SD ¼
49.5). The second most frequent ﬁrst-line chemotherapy regimen
was carboplatin and docetaxel (8.5%, n ¼ 214), in which patients
received an average of 5.5 and 5.6 cycles, respectively, and had an
average length of treatment of 100.9 days (SD ¼ 49.4). Other ﬁrst-
line therapies included a single platinum agent (ie, carboplatin or
cisplatin; 4.9%, n ¼ 122), paclitaxel alone (1.8%, n ¼ 44), cisplatin
and paclitaxel (<1%, n ¼ 21), and a platinum agent and cyclo-
phosphamide (<1%, n ¼ 16).
A large portion of ﬁrst-line patients were evidenced to have ended
treatment before 24 weeks for reasons such as having no further
evidence of ﬁrst-line chemotherapy, receiving a second-line therapy,
or having a gap in ﬁrst-line treatment of more than 10 weeks.
Approximately half of the sample successfully completed ﬁrst-line
therapy (ie, received 6 or more cycles of chemotherapy) and thus
were eligible for maintenance therapy. Additionally, the completion
rate in patients aged 65 to 74 years was 48% (n ¼ 594) and in
patients aged 75 years and older it was 43% (n ¼ 548) over the
observation period.
Maintenance Therapy
Maintenance therapy treatment patterns are shown in Table 3.
Of the 1142 patients eligible, 26.8% (306 patients) initiated
maintenance therapy. No patients received bevacizumab for main-
tenance therapy. Maintenance therapy initiation rates for patients
aged 65 to 74 years were 31% (n¼ 183) and for those aged 75 years
and older were 22% (n ¼ 123) during the observation period. Of
the 953 patients who completed the most common ﬁrst-line
regimen of carboplatin and paclitaxel, most patients (71.4%,
n ¼ 680) did not initiate maintenance chemotherapy. Of those
who did, 238 received maintenance paclitaxel, averaging 5.3 cycles
over 90.9 days (SD ¼ 101.3) and 35 received maintenancedocetaxel, averaging 4.4 cycles over 86.2 days (SD ¼ 110.4).
Patterns were similar in the patients who completed ﬁrst-line car-
boplatin and docetaxel and initiated maintenance docetaxel.
Most patients ended maintenance therapy before 52 weeks, and
approximately 10% of patients had longer than 40 weeks of
continuous maintenance therapy. The most frequent sequelae
associated with ending maintenance included receiving a second-
line therapy and having no further evidence of chemotherapy.
However, the speciﬁc reasons for no further evidence of chemo-
therapy could not be determined, because the data do not indicate if
these patients had measurable disease at the initiation of mainte-
nance treatment or if the therapy discontinuation was because of
toxicity or any other reason.
Over the remainder of the patients’ exposure time, including the
period after a patient’s treatment episode ended, approximately
73.1% (n ¼ 174) of ﬁrst-line carboplatin and paclitaxel patients
who began paclitaxel maintenance therapy had evidence of second-
line therapy, compared with 63.4% (n ¼ 431) of patients who
did not begin maintenance therapy after ﬁrst-line carboplatin
and paclitaxel. The respective time to second-line therapy was
256 (interquartile range, 156-549) and 279 (interquartile range,
128-496) days.
Second-line Therapy
Second-line treatment patterns are shown in Table 4. Of the
1890 patients beginning second-line therapy, the most frequent
second-line regimen was single agent doxorubicin (23.5%, n ¼
444), most of which was the liposomal form of doxorubicin (97%,
n ¼ 429), with an average treatment episode of 86.3 days (SD ¼
74.8). Approximately 47% of these patients received 4 or more
cycles of doxorubicin during their initial second-line treatment
episode. The second most frequent second-line chemotherapy
regimen was a platinum agent with paclitaxel (15.7%, n ¼ 296),
with an average treatment episode of 114.3 days (SD ¼ 81.0).
Approximately 80% of these patients received 4 or more cycles of
carboplatin, cisplatin, or paclitaxel during their initial second-line
treatment episode. Other second-line therapies included (in
decreasing order of frequency): a platinum agent and gemcitabine
(11.1%, n ¼ 209), topotecan (10.8%, n ¼ 205), gemcitabine
(8.6%, n ¼ 163), carboplatin (7.9%, n ¼ 149), a platinum agent
and docetaxel (5.9%, n ¼ 112), paclitaxel (2.2%, n ¼ 41), doce-
taxel (1.6%, n ¼ 30), and bevacizumab (<1%, n ¼ 14). Most
patients ended their initial second-line treatment episode because
they received a different second-line agent.
Of the 1663 patients given a speciﬁc second-line regimen, 766
(46.1%) were given a regimen delegated to platinum-sensitive
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Table 2 Ovarian Cancer First-Line Treatment Patterns, According to Regimen
Carboplatin D
Paclitaxel
Carboplatin D
Docetaxel
Carboplatin or
Cisplatin Paclitaxel
Cisplatin D
Paclitaxel
Carboplatin/
Cisplatin D
Cyclophosphamide Other
Sample, n (% of Entire Sample) 1877 (74.8) 214 (8.5) 122 (4.9) 44 (1.8) 21 (0.8) 16 (0.6) 215 (8.6)
Length of Continuous Treatment Episode (days)
Mean (SD) [Interquartile range] 103.9 (49.5)
[81.0-141.0]
100.9 (49.4)
[72.0-141.0]
89.1 (60.6)
[31.0-147.0]
79.9 (64.4)
[4.5-134.5]
101.4 (42.8)
[86.0-117.0]
91.1 (45.6)
[56.5-128.5]
119.7 (50.4)
[92.0-169.0]
Average Cycles of a Drug, Among Those Who Received the Drug During the First-Line Treatment Episode, Mean [Median] (SD)
Paclitaxel 5.5 [5.0] (3.4) e e 5.2 [4.0] (4.7) 5.9 [5.0] (3.4) e 3.4 [2.0] (2.8)
Carboplatin 5.3 [5.0] (2.9) 5.5 [6.0] (3.2) 4.6 [4.0] (3.3) e e 4.2 [4.0] (1.7) 5.3 [6.0] (2.4)
Docetaxel e 5.6 [6.0] (3.3) e e e e 3.8 [4.0] (2.7)
Cisplatin e e 2.8 [2.5] (1.5) e 3.9 [4.0] (1.8) 2.0 [2.0] (0.0) 3.6 [4.0] (1.9)
Cyclophosphamide e e e e e 3.8 [3.5] (1.6) 3.6 [4.0] (2.1)
Received First-line Drug Outside of Category
During First-line Treatment Episode, n (%)
234 (12.5) 19 (8.9) 42 (34.4) 15 (34.1) a a 69 (32.1)
Reasons for First-line Treatment Episode End, n (%)
Episode ended on or after 24 weeks of
ﬁrst-line chemotherapy
316 (16.8) 32 (15.0) 20 (16.4) a a a 65 (30.2)
Episode Ended Before 24 Weeks of First-line
Chemotherapy, n (%)
Received a second-line drug during 24-week
ﬁrst-line period
135 (7.2) a a a 0 (0.0) 0 (0.0) a
No further evidence of ﬁrst-line chemotherapy
during 24-week ﬁrst-line period
716 (38.1) 68 (31.8) 26 (21.3) a a a b
No further evidence of chemotherapy ever in
the dataset
617 (32.9) 85 (39.7) 57 (46.7) 22 (50.0) a a 70 (32.6)
Gap  10 weeks in ﬁrst-line chemotherapy
during 24-week ﬁrst-line period
93 (5.0) a a a 0 (0.0) 0 (0.0) a
Maximum Number of Cycles of the Most Used First-line Chemotherapy Drug During the First-line Treatment Episode, n (%)
1 cycle 127 (6.8) 15 (7.0) 23 (18.9) 11 (25.0) 0 (0.0) 0 (0.0) e
2 cycles 125 (6.7) 16 (7.5) a a a a e
3 cycles 135 (7.2) 14 (6.5) 17 (13.9) a a a e
4 cycles 181 (9.6) 24 (11.2) 14 (11.5) a a a e
5 cycles 356 (19.0) 22 (10.3) 23 (18.9) a a a e
6 cycles 552 (29.4) 66 (30.8) 18 (14.8) a a a e
7 to 8 cycles 222 (11.8) 31 (14.5) a a a a e
9 or more cycles 179 (9.5) 26 (12.1) a a a 0 (0.0) e
Completed First-line Therapy, n (%) 953 (50.8) 123 (57.5) 37 (30.3) 16 (36.4) a a e
aCell contents indicate n  20 patients but are suppressed to prevent cells with n < 11 from being derivable.
bCell contents indicate 65 to 80 patients but are suppressed to prevent cells with n < 11 from being derivable.
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Table 3 Ovarian Cancer Maintenance Treatment Patterns, According to Regimen
First-line Regimen Carboplatin D Paclitaxel (n [ 953) Carboplatin D Docetaxel (n [ 123)
Maintenance category Paclitaxel Docetaxel None Paclitaxel Docetaxel None
Sample, n (% of First-line Category) 238 (25.0) 35 (3.7) 680 (71.4) a 25 (20.3) b
Length of Maintenance Period (days)
Mean (SD) [Interquartile range] 90.9 (101.3) [8.0-148.0] 86.2 (110.4) [1.0-127.0] e a 98.7 (105.4) [22.0-109.0] e
Distribution of Maintenance Duration, n (% of Category)
Up to 13 weeks 160 (67.2) 24 (68.6) e a ac e
14 to 26 weeks 33 (13.9) a e a a e
27 to 39 weeks a a e a a e
40 to 51 weeks 22 (9.2) a e a a e
More than 52 weeks a a e a a e
Average Cycles of a Drug, Among Those Who Received the Drug During the Maintenance Period, Mean [Median] (SD)
Paclitaxel 5.3 [4.0] (5.0) e e a e e
Docetaxel e 4.4 [2.0] (5.7) e e 5.3 [4.0] (4.1) e
Bevacizumab e e e e e e
Distribution of Total Number of Maintenance Cycles During the Maintenance Period, n (% of Category)
1 cycle 57 (23.9) 11 (31.4) e a a e
2 cycles 33 (13.9) a e a a e
3 cycles 26 (10.9) a e a a e
4 cycles 14 (5.9) a e a a e
5 cycles 13 (5.5) a e a a e
6 or more cycles 95 (39.9) a e a a e
Reasons for Maintenance Episode End, n (%)
Episode ended on or after 52 weeks of maintenance therapy a a e a 0 (0.0) e
Episode Ended Before 52 Weeks of Maintenance Therapy, n (%)
Received second-line therapy during 52-week maintenance period 104 (43.7) a e a 12 (48.0) e
No further evidence of maintenance chemotherapy during 52-week maintenance period d a e a a e
No further evidence of chemotherapy in the dataset 66 (27.7) a e a a e
Gap  10 weeks in maintenance chemotherapy during 52-week maintenance period a a e a 0 (0.0) e
Episode ended on December 31, 2009 0 (0.0) 0 (0.0) e 0 (0.0) 0 (0.0) e
Second-line Chemotherapy Ever in the Dataset, n (%)
Evidence of second-line chemotherapy 174 (73.1) 23 (65.7) 431 (63.4) a 15 (60.0) 56c
Time From End of First-line to Second-line Drug, Among Those Who Received a Second-Line Drug (days)
Median [Interquartile range] 256.0 [156.0-549.0] 357.0 [230.0-547.0] 279.0 [128.0-496.0] 134.0 [80.0-288.0] 205.0 [87.5-433.0]
aCell contents indicate n  20 patients but are suppressed to prevent cells with n < 11 from being derivable; note that fewer than 20 patients were eligible for maintenance therapy after paclitaxel and cisplatin ﬁrst-line therapy.
bCell contents indicate 85 to 95 patients but are suppressed to prevent cells with n < 11 from being derivable.
cPercentage indicates 50% to 70% but is suppressed to prevent cells with n < 11 from being derivable.
dCell contents indicate 55 to 65 patients but are suppressed to prevent cells with n < 11 from being derivable.
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Table 4 Ovarian Cancer Second-Line Treatment Patterns, According to Regimen
Platinum
Agent D
Paclitaxel
Platinum
Agent D
Gemcitabine Carboplatin
Platinum
Agent D
Docetaxel Paclitaxel Docetaxel Doxorubicin Topotecan Gemcitabine Bevacizumab Other
Sample, n (% of
Entire Sample)
296 (15.7) 209 (11.1) 149 (7.9) 112 (5.9) 41 (2.2) 30 (1.6) 444 (23.5) 205 (10.8) 163 (8.6) 14 (0.7) 227 (12.0)
Length of Initial Second-line Treatment Episode (days)
Mean (SD)
[Interquartile range]
114.3 (81.0)
[71.0-134.5]
105.0 (65.1)
[57.0-137.0]
111.6 (122.8) 92.9 (57.4)
[45.0-120.0]
148.6 (128.8) 59.6 (51.2)
[22.0-78.0]
86.3 (74.8)
[29.0-120.0]
84.8 (86.3)
[29.0-120.0]
89.4 (70.4)
[36.0-125.0]
97.7 (112.2)
[1.0-190.0]
160.0 (170.5)
[59.0-185.0]
Maximum Number of Cycles of the Most Used Second-line Chemotherapy Drug During Initial Second-line Treatment Episode, n (% of Category)
1 cycle 16 (5.4) a a a a a 64 (14.4) a a a e
2 cycles 17 (5.7) a 21 (14.1) a a a 85 (19.1) a 16 (9.8) a e
3 cycles 26 (8.8) 14 (6.7) 15 (10.1) 18 (16.1) a a 86 (19.4) 18 (8.8) a a e
4 cycles 45 (15.2) 29 (13.9) 22 (14.8) a a a 70 (15.8) 20 (9.8) 19 (11.7) a e
5 cycles 38 (12.8) 20 (9.6) 16 (10.7) 16 (14.3) a a 41 (9.2) 12 (5.9) a a e
6 cycles 68 (23.0) 13 (6.2) 34 (22.8) 30 (26.8) a a 41 (9.2) 22 (10.7) 13 (8.0) a e
7 to 8 cycles 29 (9.8) 31 (14.8) a a a a 31 (7.0) 20 (9.8) 28 (17.2) a e
9 or more cycles 57 (19.3) 73 (34.9) 19 (12.8) 13 (11.6) 22 (53.7) a 26 (5.9) 84 (41.0) 61 (37.4) a e
Reasons for Initial Second-line Treatment Episode End, n (%)
Gap of more than 10
weeks before next
chemotherapy
c b a b a a b a a 0 (0.0) d
No further evidence
of chemotherapy
70 (23.6) 59 (28.2) 39 (26.2) 26 (23.2) a a 141 (31.8) c c a 117 (51.5)
Received a different
second-line drug
152 (51.4) 124 (59.3) 91 (61.1) 62 (55.4) 23 (56.1) 15 (50.0) 270 (60.8) 132 (64.4) 93 (57.1) a a
Episode ended on
December 31, 2009
a a a a a a a a a a a
aCell contents indicate n  20 patients but are suppressed to prevent cells with n < 11 from being derivable.
bCell contents indicate 11 to 30 patients but are suppressed to prevent cells with n < 11 from being derivable.
cCell contents indicate 55 to 70 patients but are suppressed to prevent cells with n < 11 from being derivable.
dCell contents indicate 90 to 105 patients but are suppressed to prevent cells with n < 11 from being derivable.
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Scott J. Johnson et alDiscussion
Most ovarian cancer patients, including those who achieve a
complete response after ﬁrst-line chemotherapy, will relapse and
eventually die, despite the chemosensitivity of the disease. There
continues to be a great need for therapies and treatment strategies
that can improve progression-free survival and overall survival and
are safe and tolerable. This analysis provides insight into the recent
chemotherapy treatment patterns of elderly ovarian cancer patients
during a period when ﬁrst-line treatment patterns had fully incor-
porated platinum-based agents as standard of care, maintenance
therapy was ﬁrst proposed, and angiogenesis inhibitors and other
novel agents became available.
Most patients receive combination therapy for ﬁrst-line treat-
ment. The combination of carboplatin and paclitaxel was the most
frequently used therapy, which is commonly recognized as the
standard regimen because of tolerability and activity.40
Only approximately half of the patients completed at least 6
cycles of ﬁrst-line treatment. Previous analyses in populations of
patients with ovarian cancer age 65 and older have identiﬁed rates of
chemotherapy completion in line with our estimate. Fairﬁeld et al
found that only 46.5% of ovarian cancer patients completed ﬁrst-
line chemotherapy (deﬁned as 5-6 cycles of chemotherapy), and
advanced age, disease stage, and comorbidities were major factors
associated with initiating and completing therapy.41 Similarly,
Thrall et al29 found that approximately 39.1% to 55.3% of ovarian
cancer patients received at least 6 cycles of ﬁrst-line chemotherapy
and, similar to the Fairﬁeld et al study, advanced age, disease stage,
and comorbidities were associated with the inability to complete 6
cycles of chemotherapy.41 In a retrospective review of medical re-
cords, Moore et al found that older patients were less likely to
complete therapy than their younger counterparts; 57% to 84% of
patients age 70 or older completed all 6 cycles of chemotherapy
versus 88% to 97% of patients younger than age 70, with the most
common reasons for discontinuation being intolerance or death.35
Further, in a phase II study of paclitaxel and carboplatin in pa-
tients age 70 or older, Matulonis et al found that only half of pa-
tients completed 6 cycles of carboplatin and paclitaxel with no dose
reductions, and upfront debulking surgery and comorbidities might
predict chemotherapy completion.42 Though the use of claims in
this study limits our ability to determine the speciﬁc reasons for
incomplete ﬁrst-line therapy, we found that ﬁrst-line therapy
completion rates were numerically higher in patients aged 65 to 74
compared with those 75 years and older (48% vs. 43%), potentially
indicating the negative effect of age-related comorbidities on a pa-
tient’s ability to successfully complete therapy.
The high rates of incomplete ﬁrst-line treatment also found in
our study could point to an inadequate pretreatment assessment
before chemotherapy initiation, leading to subsequent discontinu-
ation. Though some literature has indicated that the elderly are
undertreated with chemotherapy, other studies have found an
increasing propensity for elderly patients to receive primary
chemotherapy.43 Additional research should identify reasons for
incomplete therapy and methods to screen the elderly for appro-
priate treatment.
Additionally, 27% (95% conﬁdence interval, 24%-29%) of those
who ﬁnished ﬁrst-line therapy received maintenance treatment,representing only 12% of those who initiated ﬁrst-line therapy. For
those who initiated maintenance therapy, a substantial proportion
completed only a few cycles, as opposed to the annual course
initially advocated. Among the strategies to improve patient
outcome, maintenance therapy has failed to show a consistent
beneﬁt across clinical trials, and to date, the oncology community
has not come to a consensus on the beneﬁt of maintenance therapy
for ovarian cancer. In a phase III randomized trial conducted by the
Southwest Oncology Group and Gynecologic Oncology Group in
2003, Markman et al showed improved progression-free survival in
patients with advanced ovarian cancer who attained a clinically
deﬁned complete response to a platinum/paclitaxel-based mainte-
nance regimen and were subsequently administered 12 cycles of
single-agent paclitaxel.7,8 Contrary to these ﬁndings, in a similar
phase III randomized trial conducted by the After 6 Italian Coop-
erative Group, Pecorelli et al found that a regimen of 6 cycles of
maintenance paclitaxel did not improve progression-free or overall
survival in women who had achieved a complete response after ﬁrst-
line paclitaxel/platinum-based treatment.10 Additionally, in another
phase III study examining the utility of topotecan consolidation
therapy after standard carboplatin/paclitaxel chemotherapy, DePla-
cido et al showed that progression-free or overall survival were not
signiﬁcantly affected by that addition.9 The role of maintenance
therapy was controversial during this study’s observation period,
with a US Food and Drug Administration Ovarian Cancer End-
points Workshop in 2006 indicating that as many as 60% to 65%
of all patients with ovarian cancer could potentially beneﬁt from
effective maintenance therapy.44 The use of maintenance therapy
likely has a wide variability across different regions, and to our
knowledge, this study is the ﬁrst to use a nationally representative
sample to estimate rates of maintenance therapy in current practices.
There is an array of second-line regimens used for treatment, with
10 regimens describing 88.0% of patients. The next 8 most com-
mon regimens account for another 6.2% of patients. Bevacizumab is
the only therapy of those most recently available in ovarian cancer
with substantial counts, but less than 1% of patients received it.
Our data were limited to diagnoses until December 31, 2007 and
claims data until the end of 2009. Future research might observe a
different proﬁle for the use of angiogenesis inhibitors as new data
become available.
There are limitations to this analysis. There is likely measurement
error when using claims data to identify treatment received. How-
ever, previous studies have determined a high level of agreement
between Medicare claims data and chart review in the identiﬁcation
of chemotherapy among cancer patients.45 Oral drugs are omitted
in this analysis; however, these form a very small proportion of
drugs used to treat ovarian cancer, all of which are limited to po-
tential second-line therapies by the NCCN. The use of claims to
estimate treatment cycles and duration of continuous therapy also
likely is done with measurement error. If claims were improperly
ﬁlled out, our estimates of treatment duration and numbers of cycles
completed could be downwardly biased. More sensitive methods of
identifying use, such as assuming administration codes without
chemotherapy-speciﬁc codes, might result in higher estimates of
regimen completion. Important clinical information that could
be used to risk-adjust patients is not available on claims, such asClinical Ovarian and Other Gynecologic Cancer December 2012 - 75
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76 -performance status. When this information is present in SEER data,
it is recorded only at the approximate time of diagnosis and not
longitudinally over the course of the cancer. Nevertheless, SEER
Medicare data are the gold standard for observing cancer treatment
patterns in large real world samples.
Our study population is limited to women aged 65 and older.
This represents a majority of the patient population with ovarian
cancer but excludes younger patients who might have different
treatment utilization patterns than the population in our current
study. Future research investigating the treatment patterns of pa-
tients with ovarian cancer, including women younger than 65 years
of age, will enhance the generalizability of the ﬁndings.
Conclusion
We present an overview on the types of agents used to treat
elderly patients with advanced ovarian cancer for ﬁrst-line, main-
tenance, and second-line therapy. About half of patients do not
complete ﬁrst-line treatment. Most patients eligible for maintenance
therapy do not initiate it. No single treatment strategy pre-
dominates. There remains a substantial unmet need in treatment for
elderly women with ovarian cancer. Several questions remain
unanswered in this patient population, including: (1) should a
combination regimen of both a platinum and a taxane be the
standard of care in all patients; (2) are there speciﬁc predictors of
incomplete treatment; and (3) how can the barriers to completing
treatment be attenuated in this population? Continued effort in
understanding the limitations to treatment in the elderly is of
paramount importance.
Clinical Practice Points
 Over the past decade, chemotherapy treatment for patients
with advanced ovarian cancer has expanded. However, little is
known about the variation and duration of agents elderly women
receive for ﬁrst-line, maintenance, and second-line therapy. Using
SEER-Medicare data, this study provides insight into the recent
chemotherapy treatment patterns of elderly patients with
ovarian cancer.
 Most patients with advanced ovarian cancer received combina-
tion therapy for ﬁrst-line treatment, with the combination of
carboplatin and paclitaxel most common, and half of patients did
not complete ﬁrst-line therapy. Only one-quarter of those who
ﬁnished ﬁrst-line therapy received any maintenance treatment,
many of which completed only a few cycles, and no single
treatment strategy dominated second-line therapy.
 There continues to be a great need for therapies for elderly
women with ovarian cancer. Further effort is needed to identify
optimal treatment strategies in this population.Acknowledgments
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Supplementary Table 1 HCPCS Codes Used to Identify
Speciﬁc Chemotherapy Agents
Agent HCPCS Code
Carboplatin J9045
Cisplatin J9060, J9062, C9418
Cyclophosphamide J8530, J9070, J9080, J9090, J9091, J9092, J9093,
J9094, J9095, J9096, J9097, C9420, C9421
Docetaxel J9170, J9171
Paclitaxel J9264, J9265, C9127, C9431
Anastrozole S0170
Bevacizumab J9035, C9214, C9257, Q2024, S0116
Capecitabine J8520, J8521
Doxorubicin J9000, J9001, C9415
Etoposide J8560, J9181, J9182, C9414, C9425
Gemcitabine J9201
Ifosfamide J9208, C9427
Irinotecan J9206
Leuprolide J1950, J9217, J9218, J9219, C9430
Megestrol S0179
Melphalan J8600, J9245
Oxaliplatin J9263, C9205
Pemetrexed J9305, C9213
Tamoxifen S0187
Topotecan J8705, J9350, J9351
Vinorelbine J9390, C9440
Abbreviation: HCPCS ¼ Healthcare Common Procedure Coding System.
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